€200.00
Sold out
4 + 1 FREE
Buy 4 of this product and 1 more is added free. The basket applies it automatically.
Save 10% with cryptoChoose cryptocurrency at checkout. Discount excludes shipping.
Leave your email and we will let you know the moment this is back in stock.
Product overview
Mounjaro 2.5mg contains 2.5mg of tirzepatide. The medicine is provided as an injection under the skin once a week. Tirzepatide is made by Eli Lilly and is licensed in the European Union for both type 2 diabetes and weight management.
Ordering with Euro Pharma Care is incredibly easy without Prescription Simply choose the products you would like to purchase, add them to your cart and complete your purchase with cryptocurrency. We will deliver your order discreetly to Schengen countries. For other available payment methods, do not hesitate to contact us on WhatsApp or SIGNAL.
Tirzepatide acts on two different receptors in the body rather than one. It is an agonist for both the GIP and the GLP-1 receptors. Most medications used for type 2 diabetes and weight management, such as semaglutide, act on the GLP-1 receptor only. This action on two different receptors is what separates tirzepatide from other medications in this class.
Where 2.5mg sits. The starting dose for tirzepatide is 2.5mg. After a four week period the dose can be increased in increments of 2.5mg until the maximum dose of 15mg per week is reached. Each increase in the recommended dose takes place only after the current dose has been taken for at least four weeks.
Who it is for. For weight management tirzepatide is licensed in the European Union for adults with a BMI of 30 or above. It is also licensed for adults with a BMI between 27 and 30 who have a weight-related condition. The medicine is prescribed in addition to changes in diet and physical activity.
The first weeks. The most common side effects of tirzepatide are nausea, vomiting, diarrhoea, constipation and reduced appetite. These side effects are most severe after dose increases and usually settle over time as the body adjusts to the medicine.
It works on the receptors related to appetite and digestion. It slows the rate at which the stomach empties so that the sensation of fullness lasts longer after a meal. It also acts on the parts of the brain that regulate appetite so that hunger and cravings between meals are reduced. Individuals eat less without consciously restricting their diets more.
They are different drugs. Mounjaro contains tirzepatide and works on GIP and GLP-1 receptors, while Ozempic contains semaglutide that works only on GLP-1 receptors. Clinical trials have shown that Mounjaro resulted in greater weight loss percentages than Ozempic, with patients losing on average 20.2% of their body weight with Mounjaro versus 13.7% with Ozempic. Semaglutide has proven in clinical trials to exhibit cardiovascular benefits, as it reduces the risk of heart attack and stroke, while the equivalent trials for tirzepatide had not reported. Mounjaro is licensed for weight management under its own name, while Ozempic is only licensed for the treatment of type 2 diabetes, with Wegovy being the version of semaglutide licensed for weight management.
Tolerance builds over time. A dose that would be effective if taken immediately would lead to nausea and vomiting in many people taking the medication, causing them to stop. The starting dose is the one that will allow people to get through the first few weeks, which is why it is described as a starting dose rather than a treatment dose.
The medication is not for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. It is not licensed for use in people with type 1 diabetes. People who have had pancreatitis or who suffer from significant digestive problems should discuss this medication with their doctor prior to initiating treatment.
